Benn Jordan exposes a medical crisis that feels less like a policy failure and more like a dystopian thriller, arguing that the current ADHD medication shortage is not an accident of supply chains but a calculated profit strategy by pharmaceutical giants. This piece is notable because it moves beyond the standard narrative of "bureaucratic inefficiency" to present a stark, evidence-backed case where corporate opportunism is directly linked to a 19% increase in mortality risk for untreated patients.
The Human Cost of a "Shortage"
Jordan begins by dismantling the stigma surrounding adult ADHD, noting that for many high-functioning professionals, the disorder is not about an inability to focus, but an inability to improvise when plans change. "I expected Adderall to make me feel cracked out but it made me realize that I feel cracked out by default when I'm not taking it," Jordan writes, a distinction that reframes the medication from a performance enhancer to a stabilizer for a neurologically distinct brain. The author argues that the condition is predominantly hereditary and observable via MRI, yet the public perception remains stuck on outdated stereotypes of hyperactive children.
The stakes, Jordan points out, are terrifyingly high. Citing a major study, the author notes that "people receiving treatment for ADHD in the form of medication had a 19% lower risk of death than those who are not being treated." This statistic anchors the entire argument: the shortage is not merely an inconvenience; it is a public health emergency. Untreated adults face significantly higher rates of anxiety, depression, and substance abuse, while young drivers with the condition are three times more likely to cause a crash than a legally drunk driver. The author's framing is effective because it shifts the debate from "drug abuse" to "preventable mortality."
The Regulatory Blame Game
The narrative then pivots to the regulatory landscape, specifically targeting the Drug Enforcement Administration (DEA). Jordan argues that the agency's decision to cap the production of amphetamines was based on a flawed premise: that the pandemic-era expansion of telehealth led to a massive spike in abuse. "The DEA being chronically allergic to facts decided to limit the amount of amphetamines that drug companies in America can buy," Jordan writes, highlighting the lack of evidence that online prescriptions accounted for more than 1% of stimulant use. By imposing strict quotas, the executive branch effectively created a supply vacuum that the market could not fill.
Critics might note that the DEA's mandate is to prevent diversion and abuse, and that the agency may have acted on incomplete data regarding the scale of recreational use. However, Jordan's evidence suggests that the regulatory response was a sledgehammer that crushed legitimate supply lines without addressing the actual root causes of abuse, such as college students seeking study aids.
The Profit Motive in the Shadows
The most damning section of the piece investigates the pharmaceutical industry's response to the shortage. Jordan reveals that despite the DEA allowing for a higher production quota, manufacturers simply chose not to produce the full amount. "Our data showed that in 2022 manufacturers did not produce the full amount that these limits permitted them to make resulting in a shortfall of 1 billion doses," Jordan quotes from a DEA administrator's statement, pointing out the glaring discrepancy between permitted production and actual output.
The author then details a frustrating journey through the healthcare system, where insurance companies, pharmacies, and manufacturers create a labyrinth designed to extract maximum value. When Jordan's doctor switched him to a different stimulant, the manufacturer's website aggressively marketed the drug with coupons, yet insurance coverage was inconsistent and pharmacy stock was non-existent. "It is more expensive but at you the manufacturer has this coupon that works with everyone literally everyone," Jordan observes, noting the irony that the drug is accessible only through a complex web of financial maneuvering.
"Just because patients are 19% more likely to die as a result of our little drug shortage doesn't mean that y'all have the right to take it out on us shareholders."
This quote, attributed to a pharmaceutical CEO in a live stream, serves as the piece's moral climax. Jordan argues that companies are intentionally limiting the supply of generic medications to drive up demand for their more expensive, branded alternatives. The author's investigation into a specific startup, Ino Medfinder, and the rise of services that charge fees just to call pharmacies on behalf of patients, illustrates a market that has broken down so completely that access to life-saving medication has become a subscription service.
Bottom Line
Benn Jordan's argument is a powerful indictment of a system where profit incentives have been allowed to override public health imperatives. The piece's greatest strength is its refusal to accept the "supply chain" excuse, instead presenting a clear line of sight from regulatory quotas to corporate underproduction to patient harm. The biggest vulnerability lies in the difficulty of proving explicit collusion between manufacturers, yet the circumstantial evidence of underproduction despite available quotas is compelling. Readers should watch for how the executive branch responds to these findings, as the current policy trajectory appears to be worsening a crisis that is killing its own citizens.